Sophia Genetics SA (SOPH): Price and Financial Metrics


Sophia Genetics SA (SOPH): $2.29

0.02 (+0.88%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

SOPH POWR Grades

  • SOPH scores best on the Sentiment dimension, with a Sentiment rank ahead of 88.47% of US stocks.
  • SOPH's strongest trending metric is Growth; it's been moving up over the last 179 days.
  • SOPH's current lowest rank is in the Quality metric (where it is better than 3.82% of US stocks).

SOPH Stock Summary

  • With a one year PEG ratio of 0.53, SOPHIA GENETICS SA is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than only 4.94% of US stocks.
  • SOPHIA GENETICS SA's stock had its IPO on July 23, 2021, making it an older stock than merely 3.14% of US equities in our set.
  • In terms of volatility of its share price, SOPH is more volatile than 95.31% of stocks we're observing.
  • If you're looking for stocks that are quantitatively similar to SOPHIA GENETICS SA, a group of peers worth examining would be CNTG, AMST, MOTS, BASE, and AMSC.
  • To check out SOPHIA GENETICS SA's SEC filings, go to the company's page on browse-edgar?action=getcompany&CIK=0001840706.

SOPH Valuation Summary

  • In comparison to the median Technology stock, SOPH's EV/EBIT ratio is 99.47% lower, now standing at 0.1.
  • SOPH's EV/EBIT ratio has moved up 26.5 over the prior 16 months.

Below are key valuation metrics over time for SOPH.

Stock Date P/S P/B P/E EV/EBIT
SOPH 2022-11-25 3.0 0.6 -1.4 0.1
SOPH 2022-11-23 2.8 0.6 -1.4 0.1
SOPH 2022-11-22 2.8 0.6 -1.4 0.1
SOPH 2022-11-21 2.6 0.6 -1.2 0.3
SOPH 2022-11-18 2.7 0.6 -1.3 0.2
SOPH 2022-11-17 2.6 0.6 -1.2 0.3

SOPH Price Target

For more insight on analysts targets of SOPH, see our SOPH price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $23.00 Average Broker Recommendation 1.5 (Moderate Buy)

SOPH Stock Price Chart Interactive Chart >

Price chart for SOPH

SOPH Price/Volume Stats

Current price $2.29 52-week high $15.83
Prev. close $2.27 52-week low $1.68
Day low $2.20 Volume 18,000
Day high $2.44 Avg. volume 92,218
50-day MA $2.26 Dividend yield N/A
200-day MA $4.68 Market Cap 145.04M

Sophia Genetics SA (SOPH) Company Bio


Sophia Genetics SA, a cloud-based software-as-a-service platform that enables healthcare institutions to get insights from their data. The company offers SOPHiA DDM for solid tumors. Sophia Genetics SA was founded in 2012 and is based in Saint-Sulpice, Switzerland.


SOPH Latest News Stream


Event/Time News Detail
Loading, please wait...

SOPH Latest Social Stream


Loading social stream, please wait...

View Full SOPH Social Stream

Latest SOPH News From Around the Web

Below are the latest news stories about SOPHIA GENETICS SA that investors may wish to consider to help them evaluate SOPH as an investment opportunity.

SOPHiA GENETICS Third Quarter 2022 Earnings: Revenues Beat Expectations, EPS In Line

SOPHiA GENETICS ( NASDAQ:SOPH ) Third Quarter 2022 Results Key Financial Results Revenue: US$11.6m (up 12% from 3Q...

Yahoo | November 10, 2022

SOPHiA GENETICS SA (SOPH) Reports Q3 Loss, Tops Revenue Estimates

SOPHiA GENETICS SA (SOPH) delivered earnings and revenue surprises of -5.88% and 0.04%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | November 8, 2022

SOPHiA GENETICS Reports Financial Results for the Third Quarter of Fiscal 2022

Sustainable growth momentum evident despite foreign exchange headwindsBOSTON and LAUSANNE, Switzerland, Nov. 08, 2022 (GLOBE NEWSWIRE) -- SOPHiA GENETICS SA (Nasdaq: SOPH), a cloud-native software company in the healthcare space, today reported financial results for the third quarter ended September 30, 2022. Recent Highlights Revenue for the third quarter of 2022 was $11.6 million, representing year-over-year growth of 12%; constant currency revenue growth excluding COVID-19-related revenues wa

Yahoo | November 8, 2022

SOPHiA GENETICS to Participate in Upcoming November Investor Conferences

BOSTON and LAUSANNE, Switzerland, Nov. 04, 2022 (GLOBE NEWSWIRE) -- SOPHiA GENETICS SA (Nasdaq: SOPH), a cloud-native software company in the healthcare space, announced today the company will be participating in the following investor conferences. Evercore ISI HealthCONx Virtual Conference; Fireside Chat on Tuesday, November 29 at 2:15pm EST / 8:15pm CETCredit Suisse 26th Annual Technology Conference in Scottsdale, AZ; Fireside Chat on Wednesday, November 30 at 1:40pm MST / 9:40pm CET Intereste

Yahoo | November 4, 2022

SOPHiA GENETICS Partners with Microsoft to Accelerate Multimodal Health Data Analysis

SOPHiA GENETICS™ (Nasdaq: SOPH), a cloud-native software company in the healthcare space, is embarking on a multi-year integrated strategic partnership with Microsoft to improve healthcare workflows globally. This investment in the development of next- generation healthcare will lead the way in enabling multimodal data curation, development, and deployment. As a result, the Microsoft Azure-powered SOPHiA DDM™ Platform is expected to elevate the standard of care for patients, by delivering advanc

Yahoo | November 1, 2022

Read More 'SOPH' Stories Here

SOPH Price Returns

1-mo 17.44%
3-mo -24.92%
6-mo -34.76%
1-year -82.26%
3-year N/A
5-year N/A
YTD -83.76%
2021 N/A
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6926 seconds.